Concepedia
Statistics
Publications
51
Citations
3.3K
H-Index
27
Active since
2003
Affiliations
Sanofi (France)(Current)
Sanofi (United States)
Inserm
National and Kapodistrian University of Athens
Dana-Farber Cancer Institute
Sandrine Macé is an author at Sanofi (France) specializing in medicine, pharmacology, and multiple myeloma.
Publications per year
2003–2025
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations
Medicine, Hematology, Pharmacotherapy +15
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations
Medicine, Pharmacology, Pharmacotherapy +12
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. · New England Journal of Medicine · 2024 · 243 citations
Pharmacy, Hematology, Pharmacotherapy +16
The Determinants of Pre- and Postpromotion Dips in Sales of Frequently Purchased Goods
Sandrine Macé, Scott A. Neslin · Journal of Marketing Research · 2004 · 154 citations
Business, Marketing, Marketing Management +17
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja J.A. de Jonge, Vincent A. de Weger, Mark A. Dickson et al. · European Journal of Cancer · 2017 · 126 citations
Medicine, Oncology, Pharmacology +8
1–5 of 51